Symbols

NRIX

Nurix Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NRIX

Nurix Therapeutics, Inc.

A clinical-stage biopharmaceutical company that develops targeted protein modulation drugs

Industry

Biological Technology

Established Date

08/27/2009

Listing Date

07/24/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

317

Fiscal Year Ends

11-30

Website

www.nurixtx.com

Security Type

Common stock

Office address

1600 Sierra Point Parkway, Brisbane, CA 94005

Business

Introduction

Nurix Therapeutics, Inc., was incorporated in Delaware on August 27, 2009 and is headquartered in Brisbane, California. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein-degrading drugs designed to improve treatment options for patients with cancer and inflammatory diseases. Backed by an artificial intelligence (AI) integrated discovery engine and deep expertise in E3 ligase biology, the company advances a differentiated approach to translate protein degradation science into clinical therapies. Nurix's wholly-owned pipeline includes research candidates for Bruton's tyrosine kinase (BTK) and Casitas B-line lymphoma proto-oncogene B (CBL-B), as well as additional degrading agents and degrading agent antibody conjugates in preclinical development. Working with global pharmaceutical partners including Gilead Sciences, Sanofi and Pfizer, Nurix also conducts discovery programs for multiple drug candidates under co-development and co-commercialization arrangements.

Company Financials

EPS

NRIX has released its 2025 Q4 earnings. EPS was reported at -0.82, versus the expected -0.92, beating expectations. The chart below visualizes how NRIX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

NRIX has released its 2025 Q4 earnings report, with revenue of 13.58M, reflecting a YoY change of 2.21%, and net profit of -78.22M, showing a YoY change of -33.60%. The Sankey diagram below clearly presents NRIX's revenue sources and cost distribution.